Tivic Health Systems, INC 10-K annual reports

Tivic Health Systems, Inc. completed a strategic transformation in 2025, shifting from bioelectronic devices to a biopharmaceutical focus on its TLR5 agonist program Entolimod, while reporting significant losses and raising substantial doubt about its ability to continue as a going concern.

Tivic Health Systems' 2024 10-K filing details a year of strategic shifts, including a focus on bioelectronic medicine and the acquisition of a late-stage biopharmaceutical asset, alongside financial challenges and efforts to ensure future growth.

Tivic Health Systems' 2023 annual report highlights a year of strategic investments in product development and distribution, alongside financial challenges and a focus on bioelectronic medicine.